AA
KALV

AlphaCentric Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

AlphaCentric Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,500
Closed -$29.4K – 236
2024
Q2 		$29.4K Sell
2,500
-127,500
-98% -$1.49M 0.02% 214
2024
Q1 		$1.54M Sell
130,000
-7,000
-5% -$93.3K 0.93% 36
2023
Q4 		$1.68M Buy
137,000
+2,000
+1% +$18.2K 1.13% 29
2023
Q3 		$1.3M Hold
135,000
– – 0.74% 45
2023
Q2 		$1.22M Buy
+135,000
New +$1.24M 0.67% 54

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AlphaCentric Advisors's KALV Position: Q3 2024 in Review

AlphaCentric Advisors sold out of KalVista Pharmaceuticals (KALV) in Q3 2024, closing a stake of 2,500 shares — an estimated $29.4K sold.

AlphaCentric Advisors first reported a position in KALV in Q2 2023 and held it in 5 quarters. The position peaked at $1.68M in Q4 2023. 122 funds tracked by Wall St. Rank hold KALV as of Q3 2024.

  • AlphaCentric Advisors reported no remaining KalVista Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 2,500 KalVista Pharmaceuticals shares in Q3 2024, an estimated $29.4K.
  • AlphaCentric Advisors first reported a position in KalVista Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • AlphaCentric Advisors's KalVista Pharmaceuticals position peaked at $1.68M in Q4 2023.
  • 122 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.